Eltrombopag

BreastfeedingPediatric
  • TRADE NAMES: Promacta (Novartis); Revolade (Novartis)
  • INDICATIONS: Thrombocytopenic purpura, severe aplastic anemia in patients with insufficient response to immunosuppressive therapy
  • CLASS: Thrombopoietin receptor (TPO) agonist
  • HALF-LIFE: 21–32 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antacids, Atorvastatin, Dairy products, Eluxadoline, Lopinavir, Mineral supplements, Olmesartan, Rosuvastatin, Selenium, Zinc

PREGNANCY CATEGORY: C

RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C

See full prescribing information for complete boxed warning.

Our database has 65 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
RENAL
RESPIRATORY
OTHER


Page last updated 06/12/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top